BAMCO Inc’s Vaxcyte PCVX Stock Holding History

BAMCO Inc’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-25,000	Closed	-$2.05M	–	332
2024 Q4	$2.05M	Sell	25,000 -6,000	-19%	-$596K	0.01%	275
2024 Q3	$3.54M	Buy	+31,000	New	+$2.79M	0.01%	276

Other funds holding PCVX

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BAMCO Inc's PCVX Position: Q1 2025 in Review

BAMCO Inc sold out of Vaxcyte (PCVX) in Q1 2025, closing a stake of 25,000 shares — an estimated $2.05M sold.

BAMCO Inc first reported a position in PCVX in Q3 2024 and held it in 2 quarters. The position peaked at $3.54M in Q3 2024. 315 funds tracked by Wall St. Rank hold PCVX as of Q1 2025.

BAMCO Inc reported no remaining Vaxcyte position as of Q1 2025 after selling out during the quarter.
BAMCO Inc sold 25,000 Vaxcyte shares in Q1 2025, an estimated $2.05M.
BAMCO Inc first reported a position in Vaxcyte in Q3 2024 and held it in 2 quarters.
BAMCO Inc's Vaxcyte position peaked at $3.54M in Q3 2024.
315 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2025.

Based on BAMCO Inc's 13F filing for Q1 2025, filed 15 May 2025.